- Home
- Publications
- Publication Search
- Publication Details
Title
Standardized PSMA-PET Imaging of Advanced Prostate Cancer
Authors
Keywords
-
Journal
SEMINARS IN NUCLEAR MEDICINE
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-08-11
DOI
10.1053/j.semnuclmed.2023.07.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prostate-Specific Membrane Antigen Expression on Positron Emission Tomography/Computed Tomography in Patients with Metastatic Castration-Resistant Prostate Cancer: A Retrospective Observational Study
- (2023) Letizia Calderoni et al. JOURNAL OF NUCLEAR MEDICINE
- Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents
- (2023) K. Fizazi et al. ANNALS OF ONCOLOGY
- Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
- (2023) Silke Gillessen et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy
- (2023) Moon Kim et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)
- (2023) Robert Seifert et al. EUROPEAN UROLOGY
- Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study.
- (2023) Boris A. Hadaschik et al. JOURNAL OF CLINICAL ONCOLOGY
- A Prognostic Risk Score for Prostate Cancer Based on PSMA PET–derived Organ-specific Tumor Volumes
- (2023) Robert Seifert et al. RADIOLOGY
- Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer
- (2023) Andrei Gafita et al. RADIOLOGY
- Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria
- (2022) Andrei Gafita et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
- (2022) Chris C. Parker et al. PLOS MEDICINE
- PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
- (2022) James P Buteau et al. LANCET ONCOLOGY
- Is18F-FDG PET needed to assess177Lu-PSMA Therapy Eligibility? A VISION-like, Single-Center Analysis
- (2022) Robert Seifert et al. JOURNAL OF NUCLEAR MEDICINE
- A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with 18 F-DCFPyL in Prostate Cancer Patients (OSPREY)
- (2021) Kenneth J. Pienta et al. JOURNAL OF UROLOGY
- Assessing Response to [177Lu]PSMA Radioligand Therapy using modified PSMA PET Progression Criteria
- (2021) Kerstin Michalski et al. JOURNAL OF NUCLEAR MEDICINE
- The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study
- (2021) Louise Emmett et al. EUROPEAN UROLOGY
- Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
- (2021) Andrei Gafita et al. LANCET ONCOLOGY
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection
- (2021) Thomas A. Hope et al. JAMA Oncology
- Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT
- (2021) Fadi Khreish et al. Cancers
- Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial.
- (2020) Piet Ost et al. JOURNAL OF CLINICAL ONCOLOGY
- 68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy
- (2020) Désirée Deandreis et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer
- (2020) Robert Seifert et al. JOURNAL OF NUCLEAR MEDICINE
- Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
- (2020) Michael S Hofman et al. LANCET
- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2020) Cora N. Sternberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
- (2020) Ryan Phillips et al. JAMA Oncology
- PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
- (2020) Robert Seifert et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer
- (2019) Wolfgang P. Fendler et al. JAMA Oncology
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- qPSMA: a semi-automatic software for whole-body tumor burden assessment in prostate cancer using 68Ga-PSMA11 PET/CT
- (2019) Andrei Gafita et al. JOURNAL OF NUCLEAR MEDICINE
- 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients
- (2019) Christian Schmidkonz et al. ANNALS OF NUCLEAR MEDICINE
- 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
- (2019) Jeremie Calais et al. LANCET ONCOLOGY
- Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
- (2019) Wolfgang P Fendler et al. CLINICAL CANCER RESEARCH
- Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients
- (2019) Nicolas Plouznikoff et al. ANNALS OF NUCLEAR MEDICINE
- Additional local therapy of liver metastases in mCRPC patients receiving systemic PSMA targeted therapy
- (2019) Robert Seifert et al. JOURNAL OF NUCLEAR MEDICINE
- Response assessment using [ 68 Ga]Ga‐PSMA ligand PET in patients undergoing systemic therapy for metastatic castration‐resistant prostate cancer
- (2019) Bernhard Grubmüller et al. PROSTATE
- Proposal of Systemic Therapy Response Assessment Criteria in time of PSMA PET/CT imaging: PSMA PET Progression (PPP)
- (2019) Stefano Fanti et al. JOURNAL OF NUCLEAR MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rapid modulation of PSMA expression by Androgen deprivation: Serial 68Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade.
- (2018) Louise M Emmett et al. JOURNAL OF NUCLEAR MEDICINE
- Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and “whole body” tumor dosimetry with treatment outcomes
- (2018) John A Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Neuroendocrine differentiation of prostate cancer leads to PSMA suppression
- (2018) Martin K Bakht et al. ENDOCRINE-RELATED CANCER
- Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy
- (2017) Anna Katharina Seitz et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
- (2017) Matthias Eiber et al. JOURNAL OF NUCLEAR MEDICINE
- Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen–Targeted PET Imaging: PSMA-RADS Version 1.0
- (2017) Steven P. Rowe et al. JOURNAL OF NUCLEAR MEDICINE
- Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer
- (2016) Thomas Pyka et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
- (2016) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- 68 Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223 Ra: Proof of Concept
- (2016) Hojjat Ahmadzadehfar et al. JOURNAL OF NUCLEAR MEDICINE
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
- (2009) R. L. Wahl et al. JOURNAL OF NUCLEAR MEDICINE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search